Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Capital Expenditures (2020 - 2025)

Maravai Lifesciences Holdings has reported Capital Expenditures over the past 6 years, most recently at -$7.4 million for Q4 2025.

  • Quarterly results put Capital Expenditures at -$7.4 million for Q4 2025, down 225.94% from a year ago — trailing twelve months through Dec 2025 was $3.7 million (down 87.63% YoY), and the annual figure for FY2025 was $3.7 million, down 87.63%.
  • Capital Expenditures for Q4 2025 was -$7.4 million at Maravai Lifesciences Holdings, down from $9.3 million in the prior quarter.
  • Over the last five years, Capital Expenditures for MRVI hit a ceiling of $61.8 million in Q4 2023 and a floor of -$9.2 million in Q4 2022.
  • Median Capital Expenditures over the past 5 years was $3.2 million (2021), compared with a mean of $5.1 million.
  • Biggest five-year swings in Capital Expenditures: plummeted 815.12% in 2022 and later surged 813.94% in 2024.
  • Maravai Lifesciences Holdings' Capital Expenditures stood at $1.3 million in 2021, then plummeted by 815.12% to -$9.2 million in 2022, then skyrocketed by 774.11% to $61.8 million in 2023, then crashed by 90.54% to $5.8 million in 2024, then crashed by 225.94% to -$7.4 million in 2025.
  • The last three reported values for Capital Expenditures were -$7.4 million (Q4 2025), $9.3 million (Q3 2025), and -$3.5 million (Q2 2025) per Business Quant data.